Recent Investment Analysts’ Ratings Updates for AxoGen (AXGN)

AxoGen (NASDAQ: AXGN) has recently received a number of price target changes and ratings updates:

• 7/30/2026 – AxoGen had its “outperform” rating reaffirmed by Citigroup Inc..
• 7/29/2026 – AxoGen had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $55.00 price target on the stock.
• 7/26/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/18/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/4/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/6/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell sold 1,647 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $42.60, for a total value of $70,162.20. Following the sale, the director directly owned 93,826 shares of the company’s stock, valued at $3,996,987.60. This represents a 1.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathy Johnson Weiler sold 16,344 shares of AxoGen stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total transaction of $720,606.96. Following the transaction, the director directly owned 16,344 shares of the company’s stock, valued at approximately $720,606.96. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 29,041 shares of company stock worth $1,268,792. Company insiders own 2.44% of the company’s stock.

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.